The neonicotinoid insecticides acetamiprid and imidacloprid "may affect the developing human nervous system," the European Food Safety Authority said, the first time such a link has been made.
As a result, experts wanted "some guidance levels for acceptable exposure ... To be lowered while further research is carried out to provide more reliable data on developmental neurotoxicity (DNT)."
The EFSA said its opinion was based on recent research and existing data on "the potential of acetamiprid and imidacloprid to damage the developing human nervous system -- in particular the brain."
"It concluded that some current guidance levels for acceptable exposure ... May not be protective enough to safeguard against developmental neurotoxicity and should be reduced," the EFSA added.
Earlier this year, the European Union restricted the use of a series of insecticides made by Swiss chemicals giant Syngenta and its German peer Bayer on concerns they were responsible for a catastrophic decline in bee populations
In May, it banned for two years the use of imidacloprid -- cited in today's action -- and clothianidin produced by Bayer, along with thiamethoxam made by Syngenta, to treat seeds or be sprayed on soil or plants and cereals which attract bees.
Bee numbers have slumped in Europe and the United States in recent years due to a mysterious plague dubbed colony collapse disorder (CCD), sparking concerns crop pollination and so food production could be put dangerously at risk.
It is estimate bees account for some 80 per cent of plant pollination by insects.
The companies involved insist that their products are not at fault and Sygenta and Bayer said in August they would take legal action against Brussels.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
